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During the last two decades, there has been great
interest in developing and using platelet additive
solutions (PASs) for the storage of platelets.1–5 At
present, such additive solutions are in use for
transfusion in several countries.PAS is generally used as
a substitute for plasma to (1) reduce the amount of
plasma transfused with platelets and to recover plasma
for other purposes, primarily fractionation into plasma
products; (2) avoid transfusion of large volumes of
plasma with possible adverse reactions and circulatory
overload; (3) make possible photochemical treatment
for the inactivation of bacteria and other pathogens in
platelets; and (4) improve storage conditions as was
discussed in a previous review.6
A basic principle is that aging of platelets after in
vitro storage at 22°C is significantly slower than aging
of platelets in vivo at 37°C, a situation that may make
extended storage of platelets possible.7 Three
approaches were suggested to be of specific impor-
tance to improve storage conditions of platelets6: (1)
reducing the activation of platelets during collection of
blood and the preparation and storage of platelets; (2)
reducing the metabolic rate in terms of glucose
consumption and lactate production; and (3) ensuring
that glucose will be available in the storage medium
during the entire storage period. The activation of
platelets can be counteracted either by the addition of
platelet activation inhibitors or of certain components
such as magnesium to the PAS.
The use of PAS offers the possibility of including
components with specific effects on platelets in the
storage solution that are not present in plasma or in the
anticoagulant. A number of effects have been observed
that can be assigned to certain components.4,5
Reducing platelet activation and inclusion of key
components in the platelet storage environment, such
as acetate, citrate, glucose, potassium, and magnesium,
were suggested to be useful tools to optimize platelet
storage conditions. The compositions of some present
PASs are presented in Table 1. The purpose of this
review is to describe some events of the last several
years as a complement to the knowledge presented in
previous reviews.1–6
In Vivo Characteristics
Results from a number of in vivo studies using PASs
have been published during the last decade. In the first
patient transfusion studies in the 1990s using PASs
such as PAS-II (T-Sol, Baxter) or Plasma Lyte A (Table 1),
the results were not consistent.8–14 In some studies,
satisfactory CCIs were found in patient transfusion
studies,9,11 in some studies significantly lower CCIs
were observed than for platelets stored in plasma.12,14
In a recent study, encouraging platelet recovery and
survival data were found,comparing platelets prepared
by apheresis and stored in PAS-II for 1 versus 7 days.15
Mean recovery was 69 percent and 53 percent, and
survival was 8.2 and 5.1 days at Days 1 and 7,
respectively. The ratios of Day 7 to Day 1 were 0.80
and 0.65 for recovery and survival, respectively. A
proposal by Murphy16 of a new standard of efficacy for
the evaluation of platelets for transfusion has created
considerable interest. This concept implies that
acceptably stored platelets on the last day of storage
would demonstrate at least two-thirds the recovery and
one-half the survival of platelets collected from the
same subject and then retransfused as reference“fresh”
platelets. The ratios in this study15 met the proposed
criteria for 7-day storage, although the use of a Day 1
control may not totally have fulfilled the requirements
of the reference indicated.16
Comprehensive patient transfusion studies using
pathogen-reduced platelets have added significant
knowledge about platelets stored in more recent PASs,
particularly PAS-III (InterSol, Baxter). A photochemical
treatment method using a novel psoralen, amotosalen
HCl, in combination with ultraviolet light has been
developed to inactivate viruses, bacteria, protozoa, and
WBCs in platelets.17 Two major studies were
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the euroSPRITE trial in Europe and the SPRINT trial in
the United States.18–21 In the euroSPRITE trial,
comparable platelet CIs and CCIs and a comparable
safety profile for photochemically treated and
reference untreated pooled buffy-coat (BC) platelet
units in 103 oncology patients with thrombocytopenia
were demonstrated. In the SPRINT study, which
included 645 transfused patients, the hemostatic
efficacy of photochemically treated and reference
untreated platelets was found to be equivalent.19
Transfusion reactions were significantly fewer, and
adverse events and overall safety profiles were
comparable for treated and reference platelets.20 In a
second evaluation of data from the euroSPRITE patient
transfusion study using BC-derived platelets, reference
groups with untreated platelets were compared.22
Reference platelets were stored in either T-Sol (n=35)
or plasma (n=16). The results indicated that 1-hour and
24-hour mean platelet CIs and posttransfusion
hemostatic scores were not significantly different for
patients receiving platelet components suspended in
100 percent plasma and patients receiving platelets in
a T-Sol environment. In a review in 2003, the
preliminary conclusion had been that additional in vivo
data, from studies of clinical outcome after transfusion
of platelets stored in either PAS or plasma, were
needed/required.6 Today, comprehensive clinical data
support the routine use of PAS as an equivalent
alternative to plasma to suspend platelets.
In Vitro Platelet Aging at 22°C Versus In Vivo
Aging at 37°C
Because the average survival of human platelets in
the circulation, after release from megakaryocytes, is
known to be 9 to 10 days, it may be questioned
whether it is at all meaningful to extend the shelf life
of platelet concentrates up to or even beyond 7 days.23
Removal of platelets from the circulation is
believed to be age-dependent and is
probably associated with failure to maintain
normal hemostasis. Transfusion of aging
platelets may be of little help to stop
bleeding because they would be removed
from the circulation.
Studies comparing aging of platelets in
vivo with in vitro storage at 22°C, using
isotope labeling, suggested that aging of
platelets after in vitro storage for 5 days at
22°C was similar to aging of platelets during
2.1 days in vivo at 37°C.7 The relative aging
factor was found to be 0.42 (2.1 days divided by 5.0
days). In a subsequent study, a similar relative aging
factor was found (0.44).7 These differences were
associated with a much higher turnover rate of ATP, the
major energy carrier in platelets, at 37°C than at 22°C.
The calculated ATP turnover ratio of 0.48 at those two
temperatures was of the same magnitude as the
calculated relative aging factor, indicating that the
relative decrease in aging of platelets at 22°C compared
with that at 37°C is similar to the relative decrease in
metabolic rate at this temperature. The rate of aging of
platelets during storage at 22°C may be less than half of
that found in vivo at 37°C. If this ratio is applied to the
normal lifespan of platelets, 9 to 10 days in the
circulation would correspond to at least 18 to 20 days
of in vitro storage at 22°C. These data may provide
meaningful objectives to develop methods and storage
environments for extended storage of platelets.
The Use of PAS in Combination With
Different Methods for the Preparation of
Platelets for Transfusion
In general, the various PASs can be used for
apheresis as well as for BC platelets. The storage
medium normally is composed of a mixture of plasma
(generally 20–40%) and PAS (60–80%). The main
difference is that in apheresis platelets, ACD is often
preferred to CPD anticoagulant, because resuspension
of platelets after preparation is facilitated. In some
apheresis equipment, platelets are kept in the
centrifugation chamber during the entire apheresis
cycle; in other equipment, platelets are continuously
transferred to a platelet storage container. These
differences may result in significant variation in platelet
activation. Although apheresis equipment originally
may have been designed for the preparation of
platelets suspended in plasma,most equipment can be
Table 1. Composition of some current PASs (in mmol/L) including commercial
designations*
Plasma PAS-II PAS-III Composol PAS-III M
Lyte A (T-Sol, (InterSol, (Fresenius) (SSP+,
Baxter) Baxter) MacoPharma)
NaCl 90 116 77 90 69
KCl 5 – – 5 5
MgCl2 3 – – 1.5 1.5
Na3-citrate – 10 10 11 10
NaH2PO4/Na2HPO4 – – 26 – 26
Na-acetate 27 30 30 27 30
Na-gluconate 23 – – 23 –
*The compositions of commercial solutions may be slightly different from basic compositions.
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used for platelet collection in a small final resuspension
volume of plasma, which is necessary to allow the
addition of PAS. Satisfactory results were obtained by
Ringwald et al.24,25 when evaluating the suspension of
high concentrations of apheresis platelets (4000–5000
× 109 platelets/L) in PAS.
BC-derived platelets suspended in PAS are generally
prepared in pools from several donors. There are
primarily variations in the number of BCs included in
the pools (generally 3–7 BCs) and in the time of
holding of whole blood preceding the preparation of
BCs. Either BCs can be prepared on the day of
collection, generally within 8 hours, and stored
overnight for the preparation of platelets on the
following day, or whole blood can be stored overnight
for the preparation of BCs and platelets on the
following day.
The platelet rich plasma (PRP) method is generally
not used for the routine preparation of platelets in PAS.
However, in a recent study by Sweeney et al.,26 platelets
were prepared from individual donors by the PRP
method in a first step and then pooled as platelets from
several donors and suspended in either plasma or PAS.
Platelets were stored for 7 days for in vitro evaluation.
Good preservation of platelet quality in both
environments was reported.
Effects on Metabolism and Platelet Function
Associated With Components in PAS
The results of early studies by Holme et al.27 and
Gulliksson et al.28 on the effects of PAS indicated that
the presence of glucose during the entire platelet
storage period is crucial for platelet metabolism.
Effects observed after depletion of glucose involved
rapid decrease in adenine nucleotide levels, cessation
of lactate production, and finally disintegration of
platelets. Depletion of glucose is generally associated
with an increased rate of platelet metabolism and fall in
pH levels. The results suggested that depletion of
glucose, not the pH level alone, is detrimental to
platelets during storage. In contrast to plasma, the fall
in pH during storage of platelets in PAS will stop at a
significantly higher level than pH 6.0,often at about pH
6.5 as a result of the limited amount of glucose
generally available in PAS.28 Because the buffering
capacity of PAS is approximately half that of plasma,
PAS is more susceptible to increased production of
lactic acid by platelets.29,30 On the other hand,
metabolism of acetate present in PAS significantly
stabilizes the pH level. In parallel with glucose, acetate
is used as a substrate for the oxygen-dependent platelet
metabolism, and enters into the tricarboxylic acid
cycle, and is further oxidized in the respiratory
chain.29–32 The end products are carbon dioxide from
the first step and water from the second step. By
formation of bicarbonate from the carbon dioxide
produced by acetate, very stable pH levels are
maintained during platelet storage.29,30,32 A possible
third substrate for platelet metabolism may be fatty
acids.33
Generally, phosphate has two possible roles during
storage of platelets, as a stimulant of platelet glycolysis
to increase production of lactic acid and as a buffer to
prevent a fall in pH. These two effects theoretically
compete and may neutralize each other. There are no
indications of net utilization or production of
phosphate during storage of platelets.29
The new PASs designated Composol and PAS-IIIM
as well as the early Plasma Lyte A all contain
magnesium and potassium. Composol and PAS-IIIM
also contain citrate, in contrast to Plasma Lyte A. The
three components: magnesium, potassium, and citrate
are associated with complexity of effects and
interdependence. Effects on platelet membrane
function and platelet activation as well as rate of
glycolysis have been described and the various effects
may even be combined.
Increased concentration of extracellular
magnesium ions significantly inhibits exposure of P-
selectin, decreases binding of fibrinogen to ADP-
activated platelets, and significantly decreases ADP-
induced platelet aggregation.34 Magnesium may also
modify calcium influx into the platelets. In addition,
magnesium, calcium, and the concentration of citrate
have an effect on potassium permeability of the
platelet membrane and the intracellular concentration
of potassium.35 Citrate also heightens platelet
responsiveness to some activating agents such as ADP.36
In addition, effects on the rate of glucose consumption
and lactate production related to the concentration of
citrate and the presence of potassium and magnesium
in PAS have been observed. Platelets stored in medium
with a citrate concentration of 8 mmol/L produced
only half the quantity of lactate produced by platelets
in a similar medium with a citrate concentration of 14
to 26 mmol/L.37 Inasmuch as no negative effects on
adenine nucleotide levels were observed, the results
suggested that synthetic media preferably should
include citrate at low concentrations to avoid excessive
lactate production and an acid pH. On the other hand,
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increased production of lactate associated with higher
concentrations of citrate can be neutralized by the
addition of acetate.37 Again, this situation illustrates the
complexity of effects and interdependence associated
with those components. In parallel, the combination of
magnesium and potassium ions present in PAS has a
similar effect on platelets, i.e., significantly reduced
metabolic rate in terms of glucose consumption and
lactate production and also reduced platelet
activation.38–40
When platelets are shipped between different
centers,agitation may be interrupted for a considerable
period of time. A previous study using a plasma
environment suggests that possible storage time
without agitation is strongly affected by platelet
concentration.41 The level of pH should be kept above
6.5 to avoid negative effects on functional in vitro
factors such as hypotonic shock response (HSR).41 In a
recent study, the effects of interruption of agitation on
platelets stored in two PAS alternatives, namely PAS-
IIIM and Composol, were evaluated.42 At a platelet
concentration of approximately 1000 × 109/L, platelets
could be stored for 4 days in PAS-IIIM with
maintenance of HSR and pH. This was not possible
with Composol, suggesting that the presence of
phosphate is of importance to maintaining pH and
other in vitro characteristics during interruption of
agitation. Similar effects were not observed during
continuous agitation.
Future Perspectives
To conclude, present knowledge and experience
support platelet storage only at 22°C. The use of PAS
instead of plasma as the platelet storage environment
would provide benefits to patients and facilitate the
inclusion of certain components with proven favorable
effects on platelets that are present in neither plasma
nor anticoagulant. The present knowledge of effects
associated with different approaches discussed above
suggests that reducing platelet activation in
combination with the inclusion of key components in
the platelet storage medium, such as acetate, citrate,
glucose,potassium,magnesium,and additional possible
future ingredients, should be the tools to optimize the
storage conditions and maintain the function of
platelets. Additional in vivo studies of recovery and
survival as well as count increments in patients with
thrombocytopenia will be needed.
References
1. Holme S. Effect of additive solutions on platelet
biochemistry. Blood Cells 1992;18:421–30.
2. Holme S. Platelet storage in liquid environment.
Transfus Sci 1994;15:117–30.
3. Högman CF. Aspects of platelet storage. Transfus
Sci 1994;15:351–5.
4. Murphy S. The efficacy of synthetic media in the
storage of human platelets for transfusion.
Transfus Med Rev 1999;13:153–63.
5. Gulliksson H.Additive solutions for the storage of
platelets for transfusion. Transfus Med 2000;
10:257–64.
6. Gulliksson H. Defining the optimal storage
conditions for the long-term storage of platelets.
Transfus Med Rev 2003;17:209–15.
7. Holme S, Heaton WA. In vitro platelet ageing at
22°C is reduced compared to in vivo ageing at
37°C. Br J Haematol 1995;91:212–8.
8. Oksanen K, Ebeling F, Kekomäki R, et al. Adverse
reactions to platelet transfusions are reduced by
use of platelet concentrates derived from buffy
coat.Vox Sang 1994;67:356–61.
9. van Rhenen DJ,Vermeij K,Kappers-Klunne R,et al.
Evaluation of a new citrate-acetate-NaCl platelet
additive solution for the storage of white cell-
reduced platelet concentrates obtained from half-
strength CPD pooled buffy coats. Transfusion
1995;35:50–3.
10. Eriksson L,Kristensen J,Olsson K, et al. Evaluation
of platelet function using the in vitro bleeding
time and corrected count increment of transfused
platelets: comparison between platelet
concentrates derived from pooled buffy coats and
apheresis.Vox Sang 1996;70:69–75.
11. Strindberg J, Berlin G. Transfusion of platelet
concentrates: clinical evaluation of two
preparations. Eur J Haemotol 1996;57:307–11.
12. Turner VS, Mitchel SG, Hawker RJ. More on the
comparison of Plasma-Lyte A and PAS-2 as platelet
additive solutions.Transfusion 1996;36:1033–4.
13. Högman CF, Eriksson L,Wallvik J, et al. Clinical and
laboratory experience with erythrocyte and
platelet preparations from a 0.5 CPD Erythro-sol
Opti System.Vox Sang 1997;73:212–9.
14. de Wildt-Eggen J, Nauta S, Schrijver JG, et al.
Reactions and platelet increments after
transfusion of platelet concentrates in plasma or
an additive solution: a prospective, randomised
study.Transfusion 2000;40:398–403.
Platelet additive solutions
18 I M M U N O H E M A T O L O G Y, V O L U M E 2 3 , N U M B E R 1 , 2 0 0 7
15. Shanwell A, Diedrich B, Falker C, et al. Paired in
vitro and in vivo comparison of apheresis platelet
concentrates stored in platelet additive solution
for 1 versus 7 days.Transfusion 2006;46:973–9.
16. Murphy S.Radiolabeling of PLTs to assess viability:
a proposal for a standard. Transfusion 2004;44:
131–3.
17. Lin L, Cook DN, Wiesehahn GP, et al.
Photochemical inactivation of viruses and
bacteria in platelet concentrates by use of a novel
psoralen and long-wavelength ultraviolet light.
Transfusion 1997;37:423–35.
18. van Rhenen, D, Gulliksson H, Cazenave JP, et al.
Transfusion of pooled buffy coat platelet
components prepared with photochemical
pathogen inactivation treatment: the euroSPRITE
trial. Blood 2003;101:2426–33.
19. McCullough J, Vesole DH, Benjamin RJ, et al.
Therapeutic efficacy and safety of platelets treated
with a photochemical process for pathogen
inactivation. The SPRINT Trial. Blood 2004;104:
1534–41.
20. Snyder E, McCullough J, Slichter JS, et al. Clinical
safety of platelets photochemically treated with
amotosalen HCl and ultraviolet A light for
pathogen inactivation: the SPRINT trial.
Transfusion 2005;45:1864–75.
21. Janetzko K, Cazenave JP, Klüter H, et al.
Therapeutic efficacy and safety of photo-
chemically treated apheresis platelets processed
with an optimized integration set. Transfusion
2005;45:1443–52.
22. van Rhenen, DJ, Gulliksson H, Cazenave JP, et al.
Therapeutic efficacy of pooled buffy-coat platelet
components prepared and stored with a platelet
additive solution.Transfus Med 2004;14:289–95.
23. Gewirtz AM, Schick B. Platelet production and
function: megakaryocytopoiesis. In: Colman RW,
Hirsh J, Marder VJ, et al., eds. Hemostasis and
thrombosis. 3rd ed. Philadelphia: JB Lippincott,
1994:353–96.
24. Ringwald J, Walz S, Zimmermann R, et al.
Hyperconcentrated platelets stored in additive
solution: aspects on productivity and in vitro
quality.Vox Sang 2005;89:11–8.
25. Ringwald J, Duerler T, Frankow O, et al. Collection
of hyperconcentrated platelets with Trima Accel.
Vox Sang 2006;90:92–6.
26. Sweeney J, Kouttab N, Holme S, et al. Storage of
platelet-rich plasma-derived platelet concentrate
pools in plasma and additive solution.Transfusion
2006;46:835–40.
27. Holme S, Heaton WA, Courtright M. Platelet
storage lesion in second-generation containers:
correlation with platelet ATP levels. Vox Sang
1987;53:214–20.
28. Gulliksson H,Sallander S,Pedajas I, et al. Storage of
platelets in additive solutions: a new method for
storage using sodium chloride solution.
Transfusion 1992;32:435–40.
29. Shimizu T, Murphy S. Roles of acetate and
phosphate in the successful storage of platelet
concentrates prepared with an acetate-containing
additive solution.Transfusion 1993;33:304–10.
30. Bertolini F, Murphy S, Rebulla P, et al. Role of
acetate during platelet storage in a synthetic
medium.Transfusion 1992;32:152–6.
31. Guppy M, Whisson ME, Sabaratnam R, et al.
Alternative fuels for platelet storage: a metabolic
study.Vox Sang 1990;59:146–52.
32. Murphy S. The oxidation of exogenously added
organic anions by platelets facilitates maintenance
of pH during their storage for transfusion at 22°C.
Blood 1995;85:1929–35.
33. Cesar J, DiMinno G,Alam I, et al. Plasma free fatty
acid metabolism during storage of platelet con-
centrates for transfusion. Transfusion 1987;27:
434–7.
34. Gawaz M, Ott I, Reininger AJ, et al. Effects of
magnesium on platelet aggregation and adhesion.
Thromb Haemost 1994;72:912–8.
35. Weis-Fogh US. The effect of citrate, calcium, and
magnesium ions on the potassium movement
across the human platelet membrane.Transfusion
1985;25:339–42.
36. Kinlough-Rathbone RL, Packham MA, Mustard JF.
Platelet aggregation. In: Harker LA, Zimmerman
TS, eds.Methods of hematology:measurements of
platelet function.NewYork:Churchill Livingstone,
1984:64–91.
37. Gulliksson H. Storage of platelets in additive
solutions: the effect of citrate and acetate in in
vitro studies.Transfusion 1993;33:301–3.
38. deWildt-Eggen J, Schrijver JG,Bins M,et al. Storage
of platelets in additive solutions: effects of
magnesium and potassium. Transfusion 2000;42:
76–80.
H. GULLIKSSON
I M M U N O H E M A T O L O G Y, V O L U M E 2 3 , N U M B E R 1 , 2 0 0 7 19
Platelet additive solutions
39. Gulliksson H, AuBuchon JP, Vesterinen M, et al.
Storage of platelets in additive solutions: a pilot
study of the effects of potassium and magnesium.
In vitro studies.Vox Sang 2002;82:131–6.
40. Gulliksson H, AuBuchon JP, Cardigan R, et al.
Storage of platelets in additive solutions: a
multicentre study of the in vitro effects of
potassium and magnesium. Vox Sang 2003;85:
199–205.
41. Hunter S, Nixon J, Murphy S. The effect of the
interruption of agitation on platelet quality during
storage for transfusion. Transfusion 2001;41:
809–14.
42. van der Meer PF, Gulliksson H,AuBuchon JP, et al.
Interruption of agitation of platelet concentrates:
effects on in vitro parameters. Vox Sang 2005;
88:227–34.
Hans Gulliksson, PhD, Department of Clinical
Immunology and Transfusion Medicine C2 66,
Karolinska University Hospital, Huddinge, SE-141 86
Stockholm, Sweden.
Phone, Fax, and Internet Information: If you have any questions concerning Immunohematology,
Journal of Blood Group Serology and Education, or the Immunohematology Methods and Procedures
manual,contact us by e-mail at immuno@usa.redcross.org.For information concerning the National Reference
Laboratory for Blood Group Serology, including the American Rare Donor Program, please contact Sandra
Nance, by phone at (215) 451-4362, by fax at (215) 451-2538, or by e-mail at snance@usa.redcross.org
